Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: Importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature

Cancer Letters

Volumn 244, Issue 1, 2006, Pages 129-135

  Segers, Jérome ^a   Fazio, Vincent Di ^b   Ansiaux, Réginald ^a   Martinive, Philippe ^a   Feron, Olivier ^a   Wallemacq, Pierre ^b   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Chemotherapy; EPR; HPLC MS MS; Tumor microenvironment; Tumor oxygenation perfusion

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; ELECTRON SPIN RESONANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEASUREMENT; MOUSE; NONHUMAN; OXIMETRY; OXYGEN SATURATION; OXYGENATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TUMOR; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; LUNG NEOPLASMS; MALE; MICE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TANDEM MASS SPECTROMETRY; THALIDOMIDE;

EID: 33749256089     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.12.017     Document Type: Article

References (33)

1. Bikfalvi A. Significance of angiogenesis in tumor progression and metastasis. Eur. J. Cancer 31 (1995) 1101-1104
2. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
3. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2 (1996) 689-692
4. Yoon S.S., Eto H., Lin C.M., Nakamura H., Pawlik T.M., Song S.U., and Tanabe K.K. Mouse endostatin inhibits the formation of lung and liver metastasis. Cancer Res. 59 (1999) 6251-6256
5. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
6. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
7. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7 (2001) 987-989
8. Ansiaux R., Baudelet C., Jordan B.F., Beghein N., Sonveaux P., De Wever J., et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin. Cancer Res. 11 (2005) 743-750
9. Taper H.S., Woolley G.W., Teller M.N., and Lardis M.P. A new transplantable mouse liver tumor of spontaneous origin. Cancer Res. 26 (1966) 143-148
10. Gallez B., Jordan B.F., Baudelet C., and Misson P.D. Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry. Magn. Reson. Med. 42 (1999) 627-630
11. Paci A., Rieutord A., Brion F., and Prognon P. Separation methods for alkylating antineoplastic compounds. J. Chromatogr. B 764 (2001) 255-287
12. Sadagopan N., Cohen L., Roberts B., Collard W., and Omer C. Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution. J. Chromatogr. B 759 (2001) 277-284
13. Huitema A.D.R., Tibben M.M., Kerbusch T., Kettenes-van den Bosch J.J., Rodenhuis S., and Beijen J.H. Simple and selective determination of cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography. J. Chromatogr. B 745 (2000) 345-355
14. Sottani C., Turci R., Perbellini L., and Minoia C. Liquid-liquid extraction procedure for trace deremination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Commun. Mass Spectrom. 12 (1998) 1063-1068
15. Gallez B., Baudelet C., and Jordan B.F. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed. 17 (2004) 240-262
16. Teicher B.A., Holden S.A., Ara G., Dupuis N.P., Liu F., Yuan J., et al. Influence of an antiangiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int. J. Cancer 61 (2005) 732-737
17. Heere-Ress E., Boehm J., Thallinger C., Hoeller C., Wacheck V., Birner P., et al. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J. Invest. Dermatol. 125 (2005) 201-206
18. Ding Q., Kestell P., Baguley B.C., Palmer B.D., Paxton J.W., Muller G., and Ching L.-M. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother. Pharmacol. 50 (2002) 186-192
19. Murata R., Nishimura Y., and Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 37 (1997) 1107-1113
20. Ma J., Pulfer S., Li S., Chu J., Reed K., and Gallo J.M. Pharmacodynamic-mediated reduction of temolozomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 61 (2001) 5491-5498
21. Wildiers H., Guetens G., De Boeck G., Verbeken E., Landuyt B., Landuyt W., et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88 (2003) 1979-1986
22. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
23. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
24. Moore M.J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20 (1991) 194-208
25. Brock N., and Hohorst H.J. Metabolism of cyclophosphamide. Cancer 20 (1967) 900-904
26. Domeyer B.E., and Sladek N.E. Kinetic of cyclophosphamide biotransformation in vivo. Cancer Res. 40 (1980) 174-180
27. Baumann F., and Preiss R. Cyclophosphamide and related anticancer drugs. J. Chromatogr. B 764 (2001) 173-192
28. Voelcker G., Wagner T., Wientzek C., and Hohorst H.J. Pharmacokinetics of 'activated' cyclophosphamide and therapeutic efficacies. Cancer 15 (1984) 1179-1186
29. Tsambaos D., Bolsen K., Georgiou S., Monastirli A., and Goerz G. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene. Arch. Dermatol. Res. 286 (1994) 347-349
30. Swartz H.M., Khan N., Buckey J., Comi R., Gould L., Grinberg O., et al. Clinical applications of EPR: overview and perspectives. NMR Biomed. 17 (2004) 335-351
31. Padhani A.R. MRI for assessing antivascular cancer treatments. Br. J. Radiol. 73 (2003) 60-80
32. Rajendran J.G., and Krohn K.A. Imaging hypoxia and angiogenesis in tumors. Radiol. Clin. N. Am. 43 (2005) 169-187
33. Milosevic M., Fyles A., and Hill R. Interstitial fluid pressure in cervical cancer: guide to targeted therapy. Am. J. Clin. Oncol. 24 (2001) 516-521